PainReform has reported positive safety data from the first part of its two-part Phase III clinical trial of PRF-110, designed to be administered in patients undergoing bunionectomy surgery.
HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a year-end business update.